Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
- Market Cap ₹ 15,843 Cr.
- Current Price ₹ 2,085
- High / Low ₹ 2,991 / 1,500
- Stock P/E 23.0
- Book Value ₹ 513
- Dividend Yield 0.38 %
- ROCE 24.2 %
- ROE 20.9 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
- Company's median sales growth is 19.9% of last 10 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 | 2,383 | |
| Sales growth | +45% | +38% | +68% | +34% | +20% | +33% | +23% | +20% | +16% | +16% | +14% | +13% | +17% |
| 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,422 | 1,553 | |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 831 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% | 35% |
| 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 111 | 129 | |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 | 83 |
| Profit before tax | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 | 875 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% | |
| 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 700 | |
| EPS in Rs | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 90.64 |
| Dividend Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 16% |
| 3 Years: | 14% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 21% |
| 3 Years: | 19% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 20% |
| 3 Years: | 18% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 23% |
| 3 Years: | 22% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,355 | 3,887 |
| 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 221 | 5 | |
| 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 446 | 468 | |
| Total Liabilities | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 | 4,375 |
| 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 580 | 710 | |
| CWIP | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 234 | 215 |
| Investments | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 | 966 |
| 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,365 | 2,484 | |
| Total Assets | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 | 4,375 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 | |
| -23 | -6 | -36 | -69 | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 | |
| -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 | |
| Net Cash Flow | 19 | 23 | 25 | -14 | 73 | 70 | 215 | -81 | 27 | -39 | 61 | -105 |
| Free Cash Flow | 24 | 34 | 43 | 18 | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 103% | 92% | 73% | 53% | 54% | 38% | 102% | 106% | 81% | 77% | 86% | 87% |
Ratios
Consolidated / View Standalone
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | -128 | -114 | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 199 |
| ROCE % | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 24% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense (Opex) Rs. Crore |
|
|||||||||||
| R&D Expense as % of Operating Revenue % |
||||||||||||
| R&D Team Size Scientists |
||||||||||||
| Africa Revenue Mix % of Operating Revenue |
||||||||||||
| LATAM Revenue Mix % of Operating Revenue |
||||||||||||
| US Revenue Mix % of Operating Revenue |
||||||||||||
| Cumulative ANDA Approvals ANDAs |
||||||||||||
| Cumulative Product Registrations Products |
||||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Q2 FY27 earnings call transcript (held Nov 12, 2026) now available on company website.
-
Update On US FDA Inspection At The Facility Of Caplin Steriles Limited, Subsidiary Of The Company
- US FDA classified Caplin Steriles’ Gummidipoondi facility as OAI after Aug. 13–21 inspection with 10 observations.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Q2 FY2026-27 earnings call audio recording made available on November 12, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation for the Earnings Call for the Quarter and half year ended September 30, 2026
- Quarter And Half Year Ended September 30, 2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Nov 2026PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Aug 2024Transcript
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript
-
Nov 2023Transcript PPT REC
-
Nov 2023PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023PPT
-
Feb 2023PPT
-
Nov 2022Transcript REC
-
May 2021Transcript
-
Feb 2021Transcript
-
Nov 2020Transcript
-
Aug 2020Transcript PPT
-
Jun 2020Transcript
-
Oct 2019Transcript
Business Overview:[1][2][3]
Caplin Point makes and sells finished pharmaceutical formulations and APIs,
and also runs R&D and clinical research.
The group mainly serves Latin America,
Africa, the US, and other regulated markets.
Its portfolio has 5,000+ product registrations, 650+ formulations,
36 therapeutic segments, and 15+ dosage forms.